首页> 美国卫生研究院文献>Journal of Asthma and Allergy >Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial

【2h】

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial

机译：每天一次氟替卡松糠酸酯/维兰特罗组合与每日两次布地奈德/福莫特罗组合治疗控制性稳定哮喘：一项随机交叉试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionFluticasone furoate (FF)/vilanterol (VI) dry powder inhaler (DPI) is the only once-daily maintenance inhaled corticosteroid (ICS)/long-acting β2 adrenergic agonist (LABA) combination for asthma. We aimed to compare the clinical effects of once-daily FF/VI and twice-daily budesonide (BUD)/formoterol (FM) DPI in patients with controlled stable asthma.

机译：简介糠酸氟替卡松（FF）/维兰特罗（VI）干粉吸入器（DPI）是唯一每日一次维持治疗的吸入性皮质类固醇（ICS）/长效β2肾上腺素能激动剂（LABA）组合。我们旨在比较每日一次FF / VI和每日两次布地奈德（BUD）/福莫特罗（FM）DPI在控制稳定的哮喘患者中的临床效果。

著录项

期刊名称 Journal of Asthma and Allergy
作者
Kazuki Furuhashi; Tomoyuki Fujisawa; Dai Hashimoto; Yousuke Kamiya; Hideki Yasui; Masato Karayama; Yuzo Suzuki; Hironao Hozumi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda;
展开▼
作者单位

展开▼
年(卷),期 2019(12),-1
年度 2019
页码 253–261
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
fluticasone furoate/vilanterol budesonide/formoterol stable asthma randomized crossover trial inhalation adherence barriers;

机译：糠酸氟替卡松/维兰特罗;布地奈德/福莫特罗;稳定的哮喘;随机交叉试验;吸入依从性障碍;

相似文献

外文文献
中文文献
专利

1. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial [J] . Kazuki Furuhashi, Tomoyuki Fujisawa, Dai Hashimoto, Journal of Asthma and Allergy . 2019,第1期

机译：每天一次氟替卡松糠酸酯/维兰特罗组合与每日两次布地奈德/福莫特罗组合治疗控制性稳定哮喘：一项随机交叉试验
2. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [J] . Siler Thomas M., Nagai Atsushi, Scott-Wilson Catherine A., Respiratory medicine . 2017,第期

机译：一次每日氟酸甲酸呋喃/维替醇100/25μg的随机，期III试验与一次每日Vilantolol25μg评估氟酮源于COPD患者组合的氟酮源性肺功能的贡献
3. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroub of Patients from China with Symptomatic COPO at Risk of Exacerbations (FULFIL Trial) [J] . Zheng Jinping, Zhong Nanshan, Wang Changzheng, COPD: Journal of Chronic Obstructive Pulmonary Disease . 2018,第4期

机译：曾经每日氟替卡松呋喃/葡萄球菌/甲丹苷/蛋白质在来自中国患者的患者患者的两次蛋白质/福莫特酚的疗效和安全性与症状普及（履行审判）
4. Comparison of the cost -effectiveness of triamcinolone acetonide (Azmacort HFA) and fluticasone propionate (Flovent) in adult asthmatics in a randomized controlled equivalence trial [D] . Lee, Todd Allen 2001

机译：在一项随机对照试验中比较曲安奈德（Azmacort HFA）和丙酸氟替卡松（Flovent）在成年哮喘患者中的成本-效果比较
5. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy [O] . Henrik Svedsater, Gillian Stynes, Jaro Wex, 2016

机译：哮喘混合疗法中每日一次糠酸氟替卡松/维兰特罗与每日两次联合疗法的比较
6. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [O] . Thomas M. Siler, Atsushi Nagai, Catherine A. Scott-Wilson, 2017

机译：一次每日氟酸甲酸呋喃/维替者100/25μg与一次每日Vilantolol25μg的随机，期III试验，以评估氟酮源于COPD患者组合中氟酮源性的肺功能的贡献

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial

摘要

著录项

相似文献

相关主题

期刊订阅